(Q37483949)

20 August 2017

1 reference

title

Molecular-targeted therapy in malignant melanoma (English)

1 reference

20 August 2017

Ryan J Sullivan

1

1 reference

PubMed ID

19445574

20 August 2017

Michael B Atkins

series ordinal

2

1 reference

20 August 2017

1 May 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

5

1 reference

20 August 2017

567-581

1 reference

Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control

20 August 2017

1 reference

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

21 January 2018

1 reference

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.

21 January 2018

1 reference

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

21 January 2018

1 reference

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

Desmoids in familial adenomatous polyposis are monoclonal proliferations

21 January 2018

1 reference

Vindesine as a single agent in the treatment of advanced malignant melanoma

21 January 2018

1 reference

A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study

21 January 2018

1 reference

Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma.

21 January 2018

1 reference

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma

21 January 2018

1 reference

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

Raf: a strategic target for therapeutic development against cancer

21 January 2018

1 reference

Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.

21 January 2018

1 reference

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

21 January 2018

1 reference

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

21 January 2018

1 reference

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

21 January 2018

1 reference

Effectively targeting BRAF in melanoma: a formidable challenge

21 January 2018

1 reference

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

Phosphoinositide 3-kinase in disease: timing, location, and scaffolding

21 January 2018

1 reference

Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines

21 January 2018

1 reference

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.

21 January 2018

1 reference

Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice

21 January 2018

1 reference

A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors

21 January 2018

1 reference

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis

21 January 2018

1 reference

Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array

21 January 2018

1 reference

Lack of clinical efficacy of imatinib in metastatic melanoma

21 January 2018

1 reference

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas

21 January 2018

1 reference

Major response to imatinib mesylate in KIT-mutated melanoma.

21 January 2018

1 reference

Isolation of a tumor factor responsible for angiogenesis

21 January 2018

1 reference

Phase II study of thalidomide in patients with metastatic melanoma

21 January 2018

1 reference

Phase II study of thalidomide in patients with metastatic malignant melanoma.

21 January 2018

1 reference

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

21 January 2018

1 reference

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

21 January 2018

1 reference

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial

21 January 2018

1 reference

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study

21 January 2018

1 reference

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study

21 January 2018

1 reference

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).

21 January 2018

1 reference

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

21 January 2018

1 reference

Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma

21 January 2018

1 reference

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

21 January 2018

1 reference

Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma

21 January 2018

1 reference

Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells

21 January 2018

1 reference

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

21 January 2018

1 reference

BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.

21 January 2018

1 reference

The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways

21 January 2018

1 reference

Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells

21 January 2018

1 reference

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma

21 January 2018

1 reference

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

21 January 2018

1 reference

Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.

21 January 2018

1 reference

Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine

21 January 2018

1 reference

Elesclomol induces cancer cell apoptosis through oxidative stress

21 January 2018

1 reference

microRNAs exhibit high frequency genomic alterations in human cancer

21 January 2018

1 reference

Characterization of microRNA expression levels and their biological correlates in human cancer cell lines

21 January 2018

1 reference

Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas.

21 January 2018

1 reference

Phase I/II trial of tremelimumab in patients with metastatic melanoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.20

1 reference

20 August 2017

1 reference

PubMed ID

19445574